Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01683149
Show Display Options
Rank Status Study
1 Completed Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
Condition: Solid Tumor
Interventions: Drug: Topotecan;   Drug: Sorafenib

Indicates status has not been verified in more than two years